Facebook
Twitter
Telegram
Report an ErrorNabriva Therapeutics plc Balance Sheet 2011-2024 | NBRV
Annual Balance Sheet Nabriva Therapeutics plc
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-7.19 M | -39.6 M | -37.5 M | -51.3 M | -78.1 M | -86.4 M | -32.8 M | -36.6 M | 24.7 M | 11.9 M | - | - |
Long Term Debt |
388 K | 4.26 M | 2.04 M | 34.5 M | 23.7 M | 232 K | - | - | 3.45 M | 695 K | - | - |
Long Term Debt Current |
4.83 M | 3.76 M | 2.04 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
867 K | 5.22 M | 6.78 M | 36.2 M | 24 M | 435 K | 107 K | 84.2 K | 6.38 M | 9.88 M | - | - |
Total Current Liabilities |
27.6 M | 22.3 M | 18.5 M | 16.6 M | 17.8 M | 13.3 M | 15.9 M | - | - | - | - | - |
Total Liabilities |
28.5 M | 27.6 M | 25.3 M | 52.8 M | 41.8 M | 13.7 M | 16 M | 9.43 M | 41.5 M | 30.6 M | - | - |
Deferred Revenue |
- | 374 K | 750 K | - | - | - | - | 7.65 K | 7.3 K | 8.29 K | - | - |
Retained Earnings |
-653 M | -596 M | - | -477 M | -394 M | -279 M | -205 M | -137 M | -118 M | -115 M | - | - |
Total Assets |
31.8 M | 80.9 M | 58.4 M | 94.1 M | 110 M | 95.8 M | 93.2 M | 118 M | 4.82 M | 7.35 M | - | - |
Cash and Cash Equivalents |
12.4 M | 47.7 M | 41.6 M | 86 M | 102 M | 86.8 M | 32.8 M | 36.4 M | 2.15 M | - | - | - |
Book Value |
3.29 M | 53.4 M | 33.1 M | 41.3 M | 68.6 M | 82.1 M | 77.3 M | 109 M | -36.7 M | -23.2 M | - | - |
Total Shareholders Equity |
3.29 M | 53.4 M | 33.1 M | 41.3 M | 68.6 M | 82.1 M | 77.3 M | 109 M | -29 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Nabriva Therapeutics plc
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
345 K | 388 K | 399 K | - | 3.92 M | 4.26 M | 5.17 M | 6.05 M | 5.18 M | 5.69 M | 5.69 M | 5.69 M | 5.69 M | 34.5 M | 34.5 M | 34.5 M | 34.5 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 232 K | 232 K | 232 K | 232 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
697 K | 867 K | 977 K | - | 4.88 M | 5.22 M | 6.11 M | 7 M | 6.12 M | 6.78 M | 6.78 M | 6.78 M | 6.78 M | 36.2 M | 36.2 M | 36.2 M | 36.2 M | 24 M | 24 M | 24 M | 24 M | 435 K | 435 K | 435 K | 435 K | 107 K | 107 K | 107 K | 107 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
28.7 M | 28.5 M | 22.6 M | - | 21.2 M | 27.6 M | 25.8 M | 26.2 M | 24.4 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 41.8 M | 41.8 M | 41.8 M | 41.8 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | 16 M | 16 M | 16 M | 16 M | 9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | 374 K | 375 K | 563 K | 750 K | 750 K | 750 K | 750 K | 750 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-662 M | -653 M | -630 M | - | -607 M | -596 M | -583 M | -572 M | -560 M | -546 M | -546 M | -546 M | -546 M | -477 M | -477 M | -477 M | -477 M | -394 M | -394 M | -394 M | -394 M | -279 M | -279 M | -279 M | -279 M | -205 M | -205 M | -205 M | -205 M | -171 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
24.3 M | 31.8 M | 48.2 M | - | 65.8 M | 80.9 M | 89.1 M | 95.4 M | 79.4 M | 58.4 M | 58.4 M | 58.4 M | 58.4 M | 94.1 M | 94.1 M | 94.1 M | 94.1 M | 110 M | 110 M | 110 M | 110 M | 95.8 M | 95.8 M | 95.8 M | 95.8 M | 93.2 M | 93.2 M | 93.2 M | 93.2 M | 118 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
1.8 M | 12.4 M | 14.6 M | - | 34 M | 47.7 M | 52.2 M | 61.1 M | 54.8 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 86 M | 86 M | 86 M | 86 M | 102 M | 102 M | 102 M | 102 M | 86.8 M | 86.8 M | 86.8 M | 86.8 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 36.4 M | - | - | - | 2.15 M | - | - | - | 4.96 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-4.36 M | 3.29 M | 25.6 M | - | 44.6 M | 53.4 M | 63.3 M | 69.2 M | 55 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 41.3 M | 41.3 M | 41.3 M | 41.3 M | 68.6 M | 68.6 M | 68.6 M | 68.6 M | 82.1 M | 82.1 M | 82.1 M | 82.1 M | 77.3 M | 77.3 M | 77.3 M | 77.3 M | 109 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-4.36 M | 3.29 M | 25.6 M | 34.6 M | 44.6 M | 53.4 M | 63.3 M | 69.2 M | 55 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 41.3 M | 41.3 M | 41.3 M | 41.3 M | 68.6 M | 68.6 M | 68.6 M | 68.6 M | 82.1 M | 82.1 M | 82.1 M | 82.1 M | 77.3 M | 77.3 M | 77.3 M | 77.3 M | 109 M | - | - | - | -29 M | - | - | - | -18.6 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency